• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MSB
Click for more information
5.71% $1.49

MESOBLAST LIMITED - Announcements

Market Cap $1.113B  ! watchlist Created with Sketch. Add to my watchlist

Mesoblast Limited is an Australia-based company, which is engaged in developing... Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
MSB MoU for Confirmatory Trial for GI Bleeding in LVAD PatientsPRICE SENSITIVE27/03/19
MSB MSB Licensee Files For Skin Disease Marketing ApprovalPRICE SENSITIVE25/03/19
MSB Joseph R. Swedish Appointed Mesoblast Chairman22/03/19
MSB Change in substantial holding18/03/19
MSB Upcoming U.S. Investor Conferences13/03/19
MSB Mesoblast Provides Half Year Results and Corporate UpdatePRICE SENSITIVE21/02/19
MSB Half Year Financial Results Presentation21/02/19
MSB Half Year Report and Accounts (including Appendix 4D)PRICE SENSITIVE21/02/19
MSB Final Patient Dosed in Mesoblast P3 Heart Failure Trial19/02/19
MSB Mesoblast Newsletter on Advanced and End-Stage Heart Failure19/02/19
MSB Change in substantial holding11/02/19
MSB Appendix 4C - quarterlyPRICE SENSITIVE31/01/19
MSB MSB Draws US$15 Million From Existing FacilityPRICE SENSITIVE14/01/19
MSB MSB Highlights Key 2019 Priorities at U.S. Biotech Showcase08/01/19
MSB Change of Director's Interest Notices08/01/19
MSB P3 Trial of MSB's Cell Therapy in CHF Completes RecruitmentPRICE SENSITIVE07/01/19
MSB Cleansing notice and Appendix 3B07/01/19
MSB Mesoblast Corporate Review28/12/18
MSB Mesoblast to Present at 2019 Biotech Showcase in USA24/12/18
MSB MSB Makes Executive Appointment To Drive Commercialization19/12/18
MSB Meetings Held With FDA Support MSB's Planned GVHD Filing13/12/18
MSB Response to ASX queryPRICE SENSITIVE05/12/18
MSB Results of Meeting30/11/18
MSB Presentation to 2018 Annual General Meeting30/11/18
MSB Chairman's Address to Shareholders30/11/18
MSB Tasly and MSB Initiate Activities For MPC-150-IM In China26/11/18
MSB MSB Provides Q1 Financial Results and Operational HighlightsPRICE SENSITIVE16/11/18
MSB First Quarter Results Presentation16/11/18
MSB First Quarter Financial Results on Form 6-KPRICE SENSITIVE16/11/18
MSB LVAD Results Webcast PresentationPRICE SENSITIVE13/11/18
MSB LVAD Trial Results Provide Potential Regulatory PathwayPRICE SENSITIVE12/11/18
MSB Pause in TradingPRICE SENSITIVE12/11/18
MSB MSB To Host Webcast For Heart Failure Results At AHA09/11/18
MSB Appendix 4C - quarterlyPRICE SENSITIVE31/10/18
MSB Annual Report to shareholders30/10/18
MSB Notice of General Meeting/Proxy Form30/10/18
MSB Appendix 4G and Corporate Governance Statement30/10/18
MSB GVHD and CHF Updates to Emerging Leaders Conference25/10/18
MSB MSB Expands Partnership With JCR For Skin DiseasePRICE SENSITIVE24/10/18
MSB Change in substantial holding16/10/18
MSB Completion of Tasly Transaction, and Appendix 3BPRICE SENSITIVE12/10/18
MSB Release of shares from voluntary escrow11/10/18
MSB End-Stage HF Results Selected For AHA Scientific Sessions02/10/18
MSB Mesoblast Cardiac Cell Therapy In Children25/09/18
MSB Day 180 Survival Outcomes In aGvHD Phase 3 TrialPRICE SENSITIVE20/09/18
MSB Tasly Receives Approvals For Transaction With MSBPRICE SENSITIVE17/09/18
MSB Mesoblast Reports on Annual and Fourth Quarter ResultsPRICE SENSITIVE30/08/18
MSB Annual Financial Results Presentation30/08/18
MSB Preliminary Final Report including Appendix 4EPRICE SENSITIVE30/08/18
MSB UPDATE ON TASLY TRANSACTIONPRICE SENSITIVE29/08/18
MSB Appendix 4C - quarterlyPRICE SENSITIVE31/07/18
MSB Initial Director's Interest Notice18/07/18
MSB MSB Enters Into Cardiovascular Alliance For China With TaslyPRICE SENSITIVE17/07/18
MSB Director Appointment/Resignation11/07/18
MSB Appendix 3B10/07/18
MSB MSB Enters Into US$50M Financing With NovaQuest CapitalPRICE SENSITIVE02/07/18
MSB Initial and Final Directors' Interest Notices25/06/18
MSB ISSCR Presentation on P3 GVHD Trial Survival Benefits22/06/18
MSB Key Day 100 Survival Results In P3 GvHD TrialPRICE SENSITIVE21/06/18
MSB Director Appointment/Resignation19/06/18
MSB MSB Provides Q3 Financial Results and Operational Highlights31/05/18
MSB Mesoblast Appoints New Chief Financial Officer31/05/18
MSB Third Quarter Results Presentation31/05/18
MSB Third Quarter Financial Results on Form 6-KPRICE SENSITIVE31/05/18
MSB Partnership For Allogeneic Cell-based Cancer ImmunotherapiesPRICE SENSITIVE29/05/18
MSB Cleansing notice and Appendix 3B15/05/18
MSB MSB P3 Results For GVHD Presented At ISCT Meeting08/05/18
MSB MSB Cell Therapies Featured At Vatican Healthcare Conference01/05/18
MSB Appendix 4C - quarterlyPRICE SENSITIVE30/04/18
MSB MSB Clinical Program Update For MPC-150-IM In Heart Failure18/04/18
MSB Mesoblast Phase 3 CLBP Trial Completes Enrollment29/03/18
MSB Change in substantial holding09/03/18
MSB MSB Enters Into $75 Million Non-Dilutive Credit FacilityPRICE SENSITIVE07/03/18
MSB Mesoblast Provides Half Year Results and Corporate Update28/02/18
MSB Half Year Results Presentation28/02/18
MSB Half Year Report and Accounts (including Appendix 4D)PRICE SENSITIVE28/02/18
MSB GVHD Day 28 Results PresentationPRICE SENSITIVE23/02/18
MSB Primary Endpoint Successfully Achieved in MSB P3 GVHD TrialPRICE SENSITIVE22/02/18
MSB Appendix 4C - quarterlyPRICE SENSITIVE31/01/18
MSB Appendix 3B with prospectusPRICE SENSITIVE19/01/18
MSB Presentation to J.P. Morgan 2018 Healthcare Conference12/01/18
MSB Presentation at JP Morgan Healthcare Conference11/01/18
MSB Change of Director's Interest Notice22/12/17
MSB Mesoblast Receives RMAT For LVAD Heart Failure PatientsPRICE SENSITIVE21/12/17
MSB Release of shares from voluntary escrow20/12/17
MSB Mesoblast's P3 GVHD Trial Completes EnrollmentPRICE SENSITIVE20/12/17
MSB Mesoblast Grants TiGenix License For Treatment of FistulaePRICE SENSITIVE15/12/17
MSB MSB Named Global Technology Leader In Cell Therapy IndustryPRICE SENSITIVE08/12/17
MSB Change in substantial holding07/12/17
MSB Change in substantial holding05/12/17
MSB Response to ASX Aware Letter QueryPRICE SENSITIVE17/11/17
MSB Results of Meeting16/11/17
MSB CEO Presentation to 2017 Annual General Meeting16/11/17
MSB Chairman's Address to Shareholders16/11/17
MSB Ceasing to be a substantial holder15/11/17
MSB Mesoblast Provides Corporate Update and Q1 Financial ResultsPRICE SENSITIVE15/11/17
MSB First Quarter Results Presentation15/11/17
MSB First Quarter Results On Form 6KPRICE SENSITIVE15/11/17
MSB Becoming a substantial holder13/11/17
MSB RA Phase 2 Trial Results Presented At ACR Annual MeetingPRICE SENSITIVE13/11/17
MSB MoU for Confirmatory Trial for GI Bleeding in LVAD Patients
27/03/19PRICE SENSITIVE
MSB MSB Licensee Files For Skin Disease Marketing Approval
25/03/19PRICE SENSITIVE
MSB Joseph R. Swedish Appointed Mesoblast Chairman
22/03/19
MSB Change in substantial holding
18/03/19
MSB Upcoming U.S. Investor Conferences
13/03/19
MSB Mesoblast Provides Half Year Results and Corporate Update
21/02/19PRICE SENSITIVE
MSB Half Year Financial Results Presentation
21/02/19
MSB Half Year Report and Accounts (including Appendix 4D)
21/02/19PRICE SENSITIVE
MSB Final Patient Dosed in Mesoblast P3 Heart Failure Trial
19/02/19
MSB Mesoblast Newsletter on Advanced and End-Stage Heart Failure
19/02/19
MSB Change in substantial holding
11/02/19
MSB Appendix 4C - quarterly
31/01/19PRICE SENSITIVE
MSB MSB Draws US$15 Million From Existing Facility
14/01/19PRICE SENSITIVE
MSB MSB Highlights Key 2019 Priorities at U.S. Biotech Showcase
08/01/19
MSB Change of Director's Interest Notices
08/01/19
MSB P3 Trial of MSB's Cell Therapy in CHF Completes Recruitment
07/01/19PRICE SENSITIVE
MSB Cleansing notice and Appendix 3B
07/01/19
MSB Mesoblast Corporate Review
28/12/18
MSB Mesoblast to Present at 2019 Biotech Showcase in USA
24/12/18
MSB MSB Makes Executive Appointment To Drive Commercialization
19/12/18
MSB Meetings Held With FDA Support MSB's Planned GVHD Filing
13/12/18
MSB Response to ASX query
05/12/18PRICE SENSITIVE
MSB Results of Meeting
30/11/18
MSB Presentation to 2018 Annual General Meeting
30/11/18
MSB Chairman's Address to Shareholders
30/11/18
MSB Tasly and MSB Initiate Activities For MPC-150-IM In China
26/11/18
MSB MSB Provides Q1 Financial Results and Operational Highlights
16/11/18PRICE SENSITIVE
MSB First Quarter Results Presentation
16/11/18
MSB First Quarter Financial Results on Form 6-K
16/11/18PRICE SENSITIVE
MSB LVAD Results Webcast Presentation
13/11/18PRICE SENSITIVE
MSB LVAD Trial Results Provide Potential Regulatory Pathway
12/11/18PRICE SENSITIVE
MSB Pause in Trading
12/11/18PRICE SENSITIVE
MSB MSB To Host Webcast For Heart Failure Results At AHA
09/11/18
MSB Appendix 4C - quarterly
31/10/18PRICE SENSITIVE
MSB Annual Report to shareholders
30/10/18
MSB Notice of General Meeting/Proxy Form
30/10/18
MSB Appendix 4G and Corporate Governance Statement
30/10/18
MSB GVHD and CHF Updates to Emerging Leaders Conference
25/10/18
MSB MSB Expands Partnership With JCR For Skin Disease
24/10/18PRICE SENSITIVE
MSB Change in substantial holding
16/10/18
MSB Completion of Tasly Transaction, and Appendix 3B
12/10/18PRICE SENSITIVE
MSB Release of shares from voluntary escrow
11/10/18
MSB End-Stage HF Results Selected For AHA Scientific Sessions
02/10/18
MSB Mesoblast Cardiac Cell Therapy In Children
25/09/18
MSB Day 180 Survival Outcomes In aGvHD Phase 3 Trial
20/09/18PRICE SENSITIVE
MSB Tasly Receives Approvals For Transaction With MSB
17/09/18PRICE SENSITIVE
MSB Mesoblast Reports on Annual and Fourth Quarter Results
30/08/18PRICE SENSITIVE
MSB Annual Financial Results Presentation
30/08/18
MSB Preliminary Final Report including Appendix 4E
30/08/18PRICE SENSITIVE
MSB UPDATE ON TASLY TRANSACTION
29/08/18PRICE SENSITIVE
MSB Appendix 4C - quarterly
31/07/18PRICE SENSITIVE
MSB Initial Director's Interest Notice
18/07/18
MSB MSB Enters Into Cardiovascular Alliance For China With Tasly
17/07/18PRICE SENSITIVE
MSB Director Appointment/Resignation
11/07/18
MSB Appendix 3B
10/07/18
MSB MSB Enters Into US$50M Financing With NovaQuest Capital
02/07/18PRICE SENSITIVE
MSB Initial and Final Directors' Interest Notices
25/06/18
MSB ISSCR Presentation on P3 GVHD Trial Survival Benefits
22/06/18
MSB Key Day 100 Survival Results In P3 GvHD Trial
21/06/18PRICE SENSITIVE
MSB Director Appointment/Resignation
19/06/18
MSB MSB Provides Q3 Financial Results and Operational Highlights
31/05/18
MSB Mesoblast Appoints New Chief Financial Officer
31/05/18
MSB Third Quarter Results Presentation
31/05/18
MSB Third Quarter Financial Results on Form 6-K
31/05/18PRICE SENSITIVE
MSB Partnership For Allogeneic Cell-based Cancer Immunotherapies
29/05/18PRICE SENSITIVE
MSB Cleansing notice and Appendix 3B
15/05/18
MSB MSB P3 Results For GVHD Presented At ISCT Meeting
08/05/18
MSB MSB Cell Therapies Featured At Vatican Healthcare Conference
01/05/18
MSB Appendix 4C - quarterly
30/04/18PRICE SENSITIVE
MSB MSB Clinical Program Update For MPC-150-IM In Heart Failure
18/04/18
MSB Mesoblast Phase 3 CLBP Trial Completes Enrollment
29/03/18
MSB Change in substantial holding
09/03/18
MSB MSB Enters Into $75 Million Non-Dilutive Credit Facility
07/03/18PRICE SENSITIVE
MSB Mesoblast Provides Half Year Results and Corporate Update
28/02/18
MSB Half Year Results Presentation
28/02/18
MSB Half Year Report and Accounts (including Appendix 4D)
28/02/18PRICE SENSITIVE
MSB GVHD Day 28 Results Presentation
23/02/18PRICE SENSITIVE
MSB Primary Endpoint Successfully Achieved in MSB P3 GVHD Trial
22/02/18PRICE SENSITIVE
MSB Appendix 4C - quarterly
31/01/18PRICE SENSITIVE
MSB Appendix 3B with prospectus
19/01/18PRICE SENSITIVE
MSB Presentation to J.P. Morgan 2018 Healthcare Conference
12/01/18
MSB Presentation at JP Morgan Healthcare Conference
11/01/18
MSB Change of Director's Interest Notice
22/12/17
MSB Mesoblast Receives RMAT For LVAD Heart Failure Patients
21/12/17PRICE SENSITIVE
MSB Release of shares from voluntary escrow
20/12/17
MSB Mesoblast's P3 GVHD Trial Completes Enrollment
20/12/17PRICE SENSITIVE
MSB Mesoblast Grants TiGenix License For Treatment of Fistulae
15/12/17PRICE SENSITIVE
MSB MSB Named Global Technology Leader In Cell Therapy Industry
08/12/17PRICE SENSITIVE
MSB Change in substantial holding
07/12/17
MSB Change in substantial holding
05/12/17
MSB Response to ASX Aware Letter Query
17/11/17PRICE SENSITIVE
MSB Results of Meeting
16/11/17
MSB CEO Presentation to 2017 Annual General Meeting
16/11/17
MSB Chairman's Address to Shareholders
16/11/17
MSB Ceasing to be a substantial holder
15/11/17
MSB Mesoblast Provides Corporate Update and Q1 Financial Results
15/11/17PRICE SENSITIVE
MSB First Quarter Results Presentation
15/11/17
MSB First Quarter Results On Form 6K
15/11/17PRICE SENSITIVE
MSB Becoming a substantial holder
13/11/17
MSB RA Phase 2 Trial Results Presented At ACR Annual Meeting
13/11/17PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
$1.49 		Change
-0.090(5.71%) 		Mkt cap ! $1.113B
Open High Low Value Volume
$1.58 $1.59 $1.47 $7.056M 4.697M

Buyers (Bids)

No. Vol. Price($)
2 3999 $1.48
 

Sellers (Offers)

Price($) Vol. No.
$1.49 46134 7
View Market Depth
Last trade - 16.10pm 21/11/2024 (20 minute delay) ?
Last
$1.48 		  Change
-0.090 ( 5.55 %)
Open High Low Volume
$1.57 $1.57 $1.47 1111085
Last updated 15.59pm 21/11/2024 ?
MSB (ASX) Chart

Top Stories

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
Alcidion inks deal with Vic health provider Peninsula for use of Miya Precision tech Alcidion Group Ltd has signed a contract worth $3.7M to enable use of its Miya Precision platform by users of Peninsula Health entities
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.